Haemophilia

Haemophilia is a rare inherited bleeding disorder caused by deficiency of clotting factor VIII (Haemophilia A) or factor IX (Haemophilia B), leading to prolonged bleeding after injury or surgery. Extended half-life factor replacement and non-factor therapies such as emicizumab have transformed management. Gene therapy is now approved in several countries.

588
Articles
734
Trials (64 AU)
Updated
4 April 2026
Loading...

Common Questions

What is Haemophilia?

Haemophilia is a rare inherited bleeding disorder caused by deficiency of clotting factor VIII (Haemophilia A) or factor IX (Haemophilia B), leading to prolonged bleeding after injury or surgery. Extended half-life factor replacement and non-factor therapies such as emicizumab have transformed management. Gene therapy is now approved in several countries.

How many clinical trials are available for Haemophilia?

RareWays currently indexes 734 clinical trials for Haemophilia, of which 91 are actively recruiting. Trial availability changes as new studies are registered — check the trials tab for current status.

Where does the research data for Haemophilia come from?

RareWays aggregates research from PubMed, Europe PMC, OpenAlex, and ClinicalTrials.gov. Data is updated regularly by Rocky, RareWays' automated research engine. All articles and trials link directly to their original sources.

Get research updates

Monthly email when new findings are published for Haemophilia.

No spam. Unsubscribe any time. Not medical advice.

This information is for general awareness only.

For guidance specific to your situation, please speak with your healthcare team.